Login to Your Account



Final Nail in the Coffin

Ariad Suspends Iclusig Sales; Shares Take Another Tumble

By Catherine Shaffer
Staff Writer

Friday, November 1, 2013
Ariad Pharmaceuticals Inc. suspended sales of its leukemia drug Iclusig (ponatinib) due to potential blood clot issues upon request from the FDA. The discouraging news follows termination of Ariad’s Phase III EPIC trial in first-line chronic myelogenous leukemia (CML), and a clinical hold due to those same safety issues.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription